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GEOGRAPHIC VARIATION IN MEDICARE PART D PLAN ENROLLMENT,
PREMIUMS, COPAYMENT, AND COINSURANCE
Lovett A, McRae J
Mercer University, Atlanta, GA, USA
OBJECTIVES:Medicare Part D represents the single most significant expansion of a
public insurance program in 40 years. The programprovides drug coverage through
multiple private insurance plans. A key question is whether Medicare beneficiaries
choose plans based on expected premiums and out-of-pocket costs. Studies show
that about 72% of seniors consider the amount charged for each prescription as an
important factor in deciding on drug plan enrollment. Yet, few studies have ex-
plored the extent to which potential differences exist based on service region. The
objectives of this study were to: 1) examine differences in Medicare Part D premi-
ums, copay and coinsurance by geographic region, and 2) determinewhether lower
premiums, copay and coinsurancewere primary drivers for enrollee decisionmak-
ing in selection of plans. METHODS: A retrospective study design was employed
using data obtained from the Centers forMedicare andMedicaid Services. The data
was entered into SPSS 18.0 and descriptive and inferential statisticswere utilized to
examine differences. RESULTS:A total of 17million enrollees constituted the study
sample. Across all regions Medicare Part D plans utilized fixed-dollar copays more
often than coinsurance for generic and brand name drugs. The average premium
for Northeastern, Midwestern, Southern and Western region enrollees was $34,
$37, $35 and $33, respectively (p0.05). Furthermore, the average copay/coinsur-
ance for Northeastern, Midwestern, Southern and Western enrollees was $15/5%;
$14/5%; $13/6% and $14/6%, respectively (p.05). Overall, the most popular benefit
designs, chosen by 75% of enrollees, offered a premium of $39, a copay of $33 and
a coinsurance of 25%. CONCLUSIONS: Findings of this study suggest that seniors
may not always choose the plan with the lowest cost sharing. Premiums of $20,
copays of $25 and coinsurance rates of 15% have been reported in the literature as
ideal. Factors other than savings may drive Part D plan enrollment decisions.
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ELICITING PREFERENCES FOR REIMBURSED DRUGS SELECTION CRITERIA IN
COTE D’IVOIRE
Diaby V1, Lachaine J2
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2University of Montreal,
Montreal, QC, Canada
OBJECTIVES: Côte d’Ivoire, a West African country, has decided to set up a formu-
lary as part of its universal health insurance (UHI) program. One of its goals will be
to facilitate access to safe and efficacious drugs. To guarantee transparency
throughout the formulary listing process, it is important to select and value rele-
vant decision criteria for that purpose. Thus, the objective of this study was to
investigate the preferences of healthcare professionals (physicians)when selecting
reimbursable drugs and to analyze trade-offs between criteria for formulary listing
in Côte d’Ivoire.METHODS: Choice sets based on four attributes (cost effectiveness
of treatments, severity of the disease for which the treatments are indicated, age of
the population affected by diseases considered, and social class affected by dis-
eases considered [poor, rich]) were presented in a self-completion questionnaire.
RESULTS: Analysis of questionnaire responses showed that ‘cost effectiveness’,
‘severity of disease’, and ‘social class’ were significant attributes in responder’s
preferences for reimbursable drugs. More specifically, respondents’ choices were
more sensitive to drugs that are very cost effective, that target very severe disease,
and that target diseases in poor people. CONCLUSIONS: This explorative study
enabled us to elicit the preferences of a sample of healthcare professionals (physi-
cians) for reimbursed drug selection criteria in Côte d’Ivoire using the discrete-
choice experiment method. Further work is required to achieve the ultimate ob-
jective of developing a formulary for Côte d’Ivoire.
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DETERMINANTS OF PARTICIPATION IN MAMMOGRAPHY SCREENING IN
TAIWAN
Tang CH, Chuang PY, Huang YH
Taipei Medical University, Taipei, Taiwan
OBJECTIVES:Mammography screening has been considered as an effectiveway for
early detection of breast cancer to reduce themortality of breast cancer. In Taiwan,
mammography screening has been offered biennially free for woman aged 50-69
years since July 1, 2004. Nevertheless, the participation rate of mammography
screening was quite low among women eligible for this benefit, and factors that
influence beneficiaries’ decision on participation remained unknown. Thus, the
study aimed to examine major determinants associated with participation in
mammography screening among eligible women in Taiwan. METHODS: The Tai-
wan Longitudinal Health Insurance Dataset of 2005 was conducted for the study.
Women aged 50-69 years on July 1, 2004 or going to be aged 50 years during July 1,
2004 to December 31, 2009 were identified as study subjects. Age, socio-demo-
graphic characteristics, previous experience of Pap test, health-related conditions
were analyzed to evaluate the association with the likelihood of participation in
mammography screening using Cox proportional hazard model. RESULTS: There
were 106,760 beneficiaries during the observation period. Women who were with
higher wage income level, being employed, receiving Pap test in last two years,
with history of benign breast disease, and having higher Charlson Comorbidity In-
dex scorewere significantlymore likely to participate inmammography screening.
Women who were older, with breast cancer history, and residing southern part of
Taiwan were significantly less likely to participate in mammography screening.
CONCLUSIONS:Age, socio-demographic characteristics, experience of Pap test and
health-related conditions seemed to be determinants of participation inmammog-
raphy screening. Trends in participation in mammography screening by determi-
nants need to be evaluated in the future for policy makers to address the low
participation rate of mammography screening among beneficiaries.
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COMPREHENSIVE VALUE ESTIMATION OF ADALIMUMAB-BASED TREATMENTS:
COVET STUDY
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1University of Rome , Rome, Italy, 2University of Rome, Rome, Italy, 3Kingston University,
London, London, UK
BACKGROUND: The value of a drug can be expressed as the needed cost to increase
a health unit. An estimation of an index that summarize the value of a molecule
with multi-indication, however, is a complex process. OBJECTIVES: Covet study
had the specific objective of a comprehensive economic evaluation of adalimumab.
METHODS: An Econometric algorithm has been developed to estimate the total
economic value of Adalimumab. This value was calculated as the sum of the cost
per QALY gained in the treatment of rheumatoid arthritis, psoriatic arthritis, an-
kylosing spondylitis, Crohn’s disease and psoriasis. The sum was weighted by
prevalence data for each of the diseases considered. BostonMatrix has been devel-
oped to establish the relationship between demand (prevalence of the disease) and
health supply (e.g. the willingness to pay - WTP - of the health care authorities).
Finally, a League Table has been built in order to compare the cost-effectiveness of
Adalimumab with other innovative molecules. A sensitivity analysis based on the
variability of Economic Evaluation model of Adalimumab has been performed.
RESULTS: The total economic value of Adalimumab in Italy amounted to €27,700.
The sensitivity analysis showed a cost per QALY gained ranging between €19,487
and €32,453. The analysis of the Boston matrix, developed for each pathology,
indicates that the cost per QALY gained of Adalimumab was generally below the
commonWTP with the exception of psoriasis (€52,600). CONCLUSIONS: The study
provides a first indication of the total economic value of Adalimumab, that is below
the threshold value for health care interventions for all the main pathologies
treated with this molecule. Results of the study are helpful for decision makers,
who should ensure that patients have equal access to a cost-effective treatment, as
well as promote research and development of innovative molecules with greater
cost-effectiveness ratio.
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ARE HOSPITAL INPATIENT COSTS LOWER FOR MEDICARE ADVANTAGE
ENROLLEES THAN MEDICARE FEE-FOR-SERVICE BENEFICIARIES?
Karaca Z, Wong H
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
OBJECTIVES: This paper compares the private health plans that enroll Medicare
beneficiaries—known as Medicare Advantage (MA) plans— in cost to the tradi-
tionalMedicare fee-for-service (FFS) programby employing a series ofmethodolog-
ical approaches based on propensity score matching to address the moral hazard
and adverse selection issues.METHODS: The Healthcare Cost and Utilization Proj-
ect (HCUP) State Inpatient Databases (SID) were used in this analysis. We use hos-
pital inpatient data for 2008 and 2009 from California, Florida, Massachusetts, New
York, Tennessee and Wisconsin. The SID provide detailed diagnoses and proce-
dures, total charges and patient demographics for all participating states. Our key
covariate of interest is MA enrollment and the total costs associated with each
hospital visit. To obtain costs, we applied hospital specific HCUP cost-to-charge
ratios. We adjusted these costs with the CMS area wage index. We obtained infor-
mation about hospital characteristics using the American Hospital Association
Annual Survey Database; and county level information from the Area Resource
File. We estimate a baseline risk-adjusted cost model to compare the total health
care costs two cohorts in inpatient settings. To assess the robustness of our base-
line results, we re-estimated our risk-adjusted cost model following various pro-
pensity score matching methods. RESULTS: Inpatient cost for MA enrollees was
generally lower than the inpatient cost for Medicare FFS beneficiaries when moral
hazard and adverse selectionwas controlled. For example, our estimate shows that
the total health care costs per inpatient visit for MA enrollees are higher by 2.6% in
Florida, and lower by 12.6% in California when compared to Medicare FFS. We also
observed the prevalence of many chronic conditions among MA enrollees was
generally lower than amongMedicare FFS beneficiaries. CONCLUSIONS:We found
wide geographic variations in hospital inpatient costs, and in prevalence of chronic
conditions between MA enrollees and Medicare FFS beneficiaries.
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OUT-OF-POCKET DRUG EXPENDITURE AMONG USERS OF THE AMBULATORY
CARE SERVICES AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
Uc-Coyoc R, Pérez-Reynaud AG, Coello-Reyes LA, Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico
OBJECTIVES: The aim of this study is to quantify out-of-pocket drug expenditure
among ambulatory care users and to identify the variables associated with the
payment for medicines during 2010 at the Mexican Institute of Social Security.
METHODS:Data from the institutional health survey 2010was used to estimate the
total and mean drug out-of-pocket expenditure among ambulatory care users.
Statistical analysis was performed to test for mean expenditure differences by age
and gender. A binary logistic regression model was constructed to identify the
main factors related to payment for prescribed medicine. Data was aggregated
according to the marginality index estimated by the Mexican National Council of
Population to consider socio-economic regional variations. The exchange rate was
$12.34 pesos per dollar. RESULTS: A total of 71.9% of the health care users received
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